Literature DB >> 24128872

Reference range and short- and long-term biological variation of interleukin (IL)-6, IL-17A and tissue necrosis factor-alpha using high sensitivity assays.

John Todd1, Peter Simpson, Joel Estis, Victoria Torres, Alan H B Wub.   

Abstract

Interleukin (IL)-6, and tissue necrosis factor alpha (TNF-α) are established biomarkers for clinical practice and use in clinical trials of patients with cardiovascular disease. IL-17A may be an emerging marker for atherosclerosis disease progression. We measured IL-6, TNF-α, and IL-17A using a high sensitivity immunoassay (Erenna, Singulex, Inc.) to determine the reference range and to calculate the weekly (25 subjects over 6weeks) and monthly (17 subjects over 9months) biological variation (BV) from apparently healthy subjects and those attending a cardiovascular disease clinic. As a validation for the experimental and statistical approach taken, the weekly BV for high sensitivity C-reactive protein was also determined and result compared to previous reports. The upper 95th percentile reference limit for IL-6, TNF-α, and IL17-A was 4.45, 2.53, and 1.93pg/mL, respectively. The intra-individual variability ranged from 21% to 57% and the inter-individual variation ranged from 22% to 53%. The corresponding index of individuality was 0.65-1.6 and reference change values from 63% to 161%. The BV for IL-6 and TNF-α are similar to previous reports, documenting their diagnostic utility in clinical practice. Up until now, the biological variation of IL-17A and upper reference limit has not been previously reported, thereby limiting the use of this marker in clinical trials.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Biological variability; CLIA; CV(A), CV(I), CV(G); Clinical Laboratory Improvement Amendments; EDTA; HF; ICC; IL; Interleukin; LDT; LLoQ; NYHA; New York Heart Association; TNF-α; Tissue necrosis factor; analytical, intra-assay and inter-assay coefficient of variance, respectively, LoD, limit of detection; ethylenediaminetetraacetic acid; heart failure; high-sensitivity C-reactive protein; hs-CRP; interleukin; intra-class correlation coefficient; lab developed test; lower limit of quantitation; tissue necrosis factor, CVD, cardiovascular disease

Mesh:

Substances:

Year:  2013        PMID: 24128872     DOI: 10.1016/j.cyto.2013.09.018

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  21 in total

1.  Hyperpulsatile pressure, systemic inflammation and cardiac stress are associated with cardiac wall remodeling in an African male cohort: the SABPA study.

Authors:  Esmé Jansen van Vuren; Leoné Malan; Roland von Känel; Marike Cockeran; Nicolaas T Malan
Journal:  Hypertens Res       Date:  2016-05-12       Impact factor: 3.872

Review 2.  Inflammation and Nutritional Science for Programs/Policies and Interpretation of Research Evidence (INSPIRE).

Authors:  Daniel J Raiten; Fayrouz A Sakr Ashour; A Catharine Ross; Simin N Meydani; Harry D Dawson; Charles B Stephensen; Bernard J Brabin; Parminder S Suchdev; Ben van Ommen
Journal:  J Nutr       Date:  2015-04-01       Impact factor: 4.798

3.  Coronary Atherosclerosis, Cardiac Troponin, and Interleukin-6 in Patients With Chest Pain: The PROMISE Trial Results.

Authors:  Maros Ferencik; Thomas Mayrhofer; Michael T Lu; Daniel O Bittner; Hamed Emami; Stefan B Puchner; Nandini M Meyersohn; Alexander V Ivanov; Elizabeth C Adami; Deepak Voora; Geoffrey S Ginsburg; James L Januzzi; Pamela S Douglas; Udo Hoffmann
Journal:  JACC Cardiovasc Imaging       Date:  2022-05-11

4.  Inflammatory cytokines IL-6 and TNF-α in patients with hip fracture.

Authors:  D Saribal; F S Hocaoglu-Emre; S Erdogan; N Bahtiyar; S Caglar Okur; M Mert
Journal:  Osteoporos Int       Date:  2019-01-30       Impact factor: 4.507

5.  The predictive role of Interleukin 6 in burn patients with positive blood cultures.

Authors:  Jochen Gille; Jovan Jocovic; Thomas Kremer; Armin Sablotzki
Journal:  Int J Burns Trauma       Date:  2021-04-15

6.  A Randomized Controlled Trial of Long-Term (R)-α-Lipoic Acid Supplementation Promotes Weight Loss in Overweight or Obese Adults without Altering Baseline Elevated Plasma Triglyceride Concentrations.

Authors:  Gerd Bobe; Alexander J Michels; Wei-Jian Zhang; Jonathan Q Purnell; Clive Woffendin; Cliff Pereira; Joseph A Vita; Nicholas O Thomas; Maret G Traber; Balz Frei; Tory M Hagen
Journal:  J Nutr       Date:  2020-09-01       Impact factor: 4.798

7.  Prevalence of glutamine deficiency in ICU patients: a cross-sectional analytical study.

Authors:  Arista Nienaber; Robin Claire Dolman; Averalda Eldorine van Graan; Renee Blaauw
Journal:  Nutr J       Date:  2016-08-02       Impact factor: 3.271

8.  Meta-Analysis for the Association between Polymorphisms in Interleukin-17A and Risk of Coronary Artery Disease.

Authors:  Mei-Hua Bao; Huai-Qing Luo; Ju Xiang; Liang Tang; Li-Ping Dong; Guang-Yi Li; Jie Zeng; Jian-Ming Li
Journal:  Int J Environ Res Public Health       Date:  2016-06-30       Impact factor: 3.390

9.  Ficolin-2 inhibitors are present in sera after prolonged storage at -80 °C.

Authors:  Kimball Aaron Geno; Richard E Kennedy; Patricia Sawyer; Cynthia J Brown; Moon H Nahm
Journal:  PeerJ       Date:  2016-11-17       Impact factor: 2.984

Review 10.  Biomarkers in Sports and Exercise: Tracking Health, Performance, and Recovery in Athletes.

Authors:  Elaine C Lee; Maren S Fragala; Stavros A Kavouras; Robin M Queen; John Luke Pryor; Douglas J Casa
Journal:  J Strength Cond Res       Date:  2017-10       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.